신경 성장인자 시장 보고서(2025년)
Nerve Growth Factor Global Market Report 2025
상품코드 : 1730962
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,661,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,629,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,596,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

신경 성장인자 시장 규모는 향후 수년간 강력한 성장이 전망될 예정입니다. 예측 기간 동안의 성장은 바이오 의약품에 대한 수요 증가, 자가 면역 신경계 질환의 유병률 증가, 신경 염증 연구에 대한 집중, AI 기반 신약 발견에 대한 투자 증가, NGF 기반 치료제에 대한 소비자 수요 증가에 기인할 수 있습니다.

신경 질환의 유병률 증가는 신경 성장인자 시장의 성장을 가속할 것으로 예측됩니다. 장애의 유병률 증가는 주로 인구의 고령화와 진단 기술의 진보로 인한 것입니다. NGF는 신경세포의 유지, 생존 및 재생에 중요한 역할을 하며, 신경 회복을 촉진하고 잠재적으로 질병 진행을 늦춤으로써 신경 질환을 해결하는 데 필수적인 역할을 합니다. 예를 들어, 2024년 9월 호주 보건 복지 연구소는 호주의 치매 환자가 2023년 약 41만 1,100명에서 2058년에는 84만 9,300명으로 증가할 것으로 예상했습니다.

신경 성장인자 시장의 각 회사는 NGF 단일클론항체와 같은 NGF를 억제하여 효과적인 통증 완화를 제공하기 위한 첨단 제품의 개발에 주력하고 있습니다. 이러한 단일 클론 항체는 NGF를 표적으로 삼고 중화하여 수용체와의 상호 작용을 차단하여 신경의 통증과 염증을 줄이도록 설계된 생물학적 약물입니다. 이 접근법은 통증 신호 전달을 조정하고 신경 세포의 생존을 지원하는 데 도움이 됩니다. 2022년 2월, 중국에 본사를 둔 바이오 제약 회사인 Akeso는 인간화된 IgG1 단일 클론 항체인 AK115를 출시했습니다. AK115는 NGF와 수용체와의 상호작용을 저해함으로써 작용하며, 특히 오피오이드 저항성 암 환자에게 장기적이고 비중독성 통증 완화를 제공하여 QOL 향상을 목표로 합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KTH
영문 목차

영문목차

Nerve growth factor (NGF) is a protein crucial for the growth, maintenance, and survival of nerve cells, particularly sensory and sympathetic neurons. It plays an essential role in the development of the nervous system and supports the regeneration of nerve cells following injury. NGF binds to specific receptors on nerve cells, activating pathways that aid in cell survival and differentiation.

The main types of nerve growth factors include alpha-nerve growth factor (NGF), beta-nerve growth factor (NGF), gamma-nerve growth factor (NGF), and others. Alpha-NGF is a protein vital for the growth and survival of neurons, as well as the development of the peripheral nervous system. It encompasses various agents, such as cenegermin, used for conditions such as neurodegenerative disorders, spinal cord injuries, eye disorders, epithelial diseases, tissue healing, and more. These treatments are distributed through multiple channels, including hospital pharmacies, online pharmacies, and retail pharmacies, and are utilized by a range of end users, including hospitals, home care settings, specialty clinics, and others.

The nerve growth factor market research report is one of a series of new reports from The Business Research Company that provides nerve growth factor market statistics, including the nerve growth factor industry global market size, regional shares, competitors with the nerve growth factor market share, detailed nerve growth factor market segments, market trends, and opportunities, and any further data you may need to thrive in the nerve growth factor industry. This nerve growth factor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The nerve growth factor (NGF) market size has grown strongly in recent years. It will grow from $1.11 billion in 2024 to $1.20 billion in 2025 at a compound annual growth rate (CAGR) of 8.4%. The growth observed during the historic period can be attributed to factors such as the rising incidence of traumatic brain injuries, the increasing prevalence of neurodegenerative diseases, greater investments in research and development, heightened awareness of nerve regeneration therapies, and a growing incidence of peripheral neuropathy.

The nerve growth factor (NGF) market size is expected to see strong growth in the next few years. It will grow to $1.63 billion in 2029 at a compound annual growth rate (CAGR) of 8.0%. The growth during the forecast period can be attributed to the rising demand for biopharmaceuticals, an increase in the prevalence of autoimmune neurological disorders, a greater focus on neuroinflammation research, rising investments in AI-driven drug discovery, and growing consumer demand for NGF-based therapies. Key trends expected during the forecast period include advancements in biotechnology, personalized medicine strategies, innovative drug delivery systems, regulatory approvals, and the development of NGF antibodies.

The rising prevalence of neurological disorders is expected to drive the growth of the nerve growth factor (NGF) market. Neurological disorders, which impact the brain, spinal cord, and nerves, are caused by structural, biochemical, or electrical abnormalities. The growing prevalence of these disorders is mainly attributed to aging populations and advancements in diagnostic technologies. These technological improvements enhance the detection and reporting of neurological disorders, leading to a higher documented incidence. NGF plays a vital role in the maintenance, survival, and regeneration of neurons, making it essential for addressing neurological conditions by promoting neural repair and potentially slowing disease progression. For example, in September 2024, the Australian Institute of Health and Welfare projected that dementia cases in Australia would increase from approximately 411,100 in 2023 to 849,300 by 2058. As a result, the increasing prevalence of neurological disorders is contributing to the expansion of the NGF market.

Companies in the NGF market are focused on developing advanced products, such as NGF monoclonal antibodies, to inhibit NGF and provide effective pain relief. These monoclonal antibodies are biological drugs designed to target and neutralize NGF, blocking its interaction with receptors to reduce pain and inflammation in nerves. This approach helps regulate pain signaling and supports nerve cell survival. For instance, in February 2022, Akeso, Inc., a China-based biopharmaceutical company, introduced AK115, a humanized IgG1 monoclonal antibody. This antibody received approval from China's National Medical Products Administration to begin clinical trials for pain treatment, including cancer-related pain. AK115 works by blocking NGF's interaction with receptors, aiming to offer long-term, non-addictive pain relief, particularly for opioid-resistant cancer patients, thus enhancing their quality of life.

In June 2023, Dompe Farmaceutici, an Italy-based company known for developing the first recombinant human nerve growth factor, partnered with FarmaMondo Group to expand access to Oxervate (cenegermin). Through this partnership, FarmaMondo became the exclusive distributor of Oxervate in certain countries, making it more accessible for patients with neurotrophic keratitis outside the U.S., Canada, Italy, China, and Switzerland. FarmaMondo Group, a Switzerland-based pharmaceutical services provider, specializes in offering care services for rare diseases. This collaboration helps broaden access to NGF treatments for those in need.

Major players in the nerve growth factor market are Pfizer Inc., AstraZeneca Plc, Eli Lilly & Company, Teva Pharmaceutical Industries, Regeneron Pharmaceuticals Inc., Genetech, Dompe farmaceutici S.p.A., Promega Corporation, Akeso Inc, CUSABIO TECHNOLOGY LLC, Staidson Beijing BioPharmaceuticals, Biocare Medical LLC, Beike Biotechnology, Enzo Life Sciences Inc., Genexis Biotech Pvt. Ltd., Mimetogen Pharmaceuticals, Alomone Labs, MimeTech Srl, Herantis Pharma, Prospec-Tany Technogene Ltd., PainCeptor Pharma.

Asia-Pacific was the largest region in the nerve growth factor market in 2024. The regions covered in nerve growth factor report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the nerve growth factor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The nerve growth factor market consists of sales of nerve growth factor protein supplements, nerve growth factor enriched cell culture media, nerve growth factor biomarker detection kits, and diagnostic assays. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Nerve Growth Factor Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on nerve growth factor market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for nerve growth factor ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The nerve growth factor market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Nerve Growth Factor Market Characteristics

3. Nerve Growth Factor Market Trends And Strategies

4. Nerve Growth Factor Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Nerve Growth Factor Growth Analysis And Strategic Analysis Framework

6. Nerve Growth Factor Market Segmentation

7. Nerve Growth Factor Market Regional And Country Analysis

8. Asia-Pacific Nerve Growth Factor Market

9. China Nerve Growth Factor Market

10. India Nerve Growth Factor Market

11. Japan Nerve Growth Factor Market

12. Australia Nerve Growth Factor Market

13. Indonesia Nerve Growth Factor Market

14. South Korea Nerve Growth Factor Market

15. Western Europe Nerve Growth Factor Market

16. UK Nerve Growth Factor Market

17. Germany Nerve Growth Factor Market

18. France Nerve Growth Factor Market

19. Italy Nerve Growth Factor Market

20. Spain Nerve Growth Factor Market

21. Eastern Europe Nerve Growth Factor Market

22. Russia Nerve Growth Factor Market

23. North America Nerve Growth Factor Market

24. USA Nerve Growth Factor Market

25. Canada Nerve Growth Factor Market

26. South America Nerve Growth Factor Market

27. Brazil Nerve Growth Factor Market

28. Middle East Nerve Growth Factor Market

29. Africa Nerve Growth Factor Market

30. Nerve Growth Factor Market Competitive Landscape And Company Profiles

31. Nerve Growth Factor Market Other Major And Innovative Companies

32. Global Nerve Growth Factor Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Nerve Growth Factor Market

34. Recent Developments In The Nerve Growth Factor Market

35. Nerve Growth Factor Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기